NASDAQ:BLFS

BioLife Solutions Stock Forecast, Price & News

$42.73

+2.13 (+5.25 %)

(As of 01/21/2021 12:00 AM ET)

Add

Compare

Today's Range

$39.46

Now: $42.73▼

$44.31

50-Day Range

$36.54

MA: $41.20▼

$45.75

52-Week Range

$7.37

Now: $42.73▼

$47.22

Volume372,772 shs

Average Volume313,529 shs

Market Capitalization$1.40 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.55

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

MarketRank^™

Overall MarketRank^™

1.86 out of 5 stars

Medical Sector

106th out of 1,926 stocks

Electromedical Equipment Industry

4th out of 61 stocks

1.4 Analyst's Opinion

Consensus Rating
BioLife Solutions has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.44, BioLife Solutions has a forecasted downside of 24.1% from its current price of $42.73.
Amount of Analyst Coverage
BioLife Solutions has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
BioLife Solutions has received 281 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BioLife Solutions has received 235 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BioLife Solutions has received 54.46% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote “Outperform” if you believe BLFS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BioLife Solutions does not currently pay a dividend.
Dividend Growth
BioLife Solutions does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLife Solutions insiders have bought 22.97% more of their company's stock than they have sold. Specifically, they have bought $36,000,000.00 in company stock and sold $29,276,474.00 in company stock.
Percentage Held by Insiders
Only 22.30% of the stock of BioLife Solutions is held by insiders.
Percentage Held by Institutions
67.66% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for BioLife Solutions are expected to grow by 700.00% in the coming year, from $0.01 to $0.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLife Solutions is -58.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLife Solutions is -58.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
BioLife Solutions has a PEG Ratio of 50.41. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
BioLife Solutions has a P/B Ratio of 20.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BLFS

Previous Symbol

CUSIPN/A

CIK834365

Webwww.biolifesolutions.com

Phone425-402-1400

Employees54

Debt

Debt-to-Equity RatioN/A

Current Ratio15.28

Quick Ratio13.96

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio4,273.00

P/E Growth50.41

Sales & Book Value

Annual Sales$27.37 million

Price / Sales51.11

Cash Flow$0.21 per share

Price / Cash Flow200.93

Book Value$2.12 per share

Price / Book20.16

Profitability

EPS (Most Recent Fiscal Year)$0.08

Net Income$-1,660,000.00

Net Margins12.67%

Return on Equity0.53%

Return on Assets0.43%

Miscellaneous

Outstanding Shares32,736,000

Market Cap$1.40 billion

Next Earnings Date3/10/2021 (Estimated)

OptionableNot Optionable

$42.73

+2.13 (+5.25 %)

(As of 01/21/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

How has BioLife Solutions' stock price been impacted by Coronavirus?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLFS shares have increased by 248.8% and is now trading at $42.73.
View which stocks have been most impacted by COVID-19.

Is BioLife Solutions a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioLife Solutions?

Wall Street analysts have given BioLife Solutions a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLife Solutions wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as BioLife Solutions' CEO?

1,448 employees have rated BioLife Solutions CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among BioLife Solutions' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for BioLife Solutions.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings results on Thursday, November, 5th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.02). The medical equipment provider earned $11.28 million during the quarter, compared to analyst estimates of $10.71 million. BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%.
View BioLife Solutions' earnings history.

What price target have analysts set for BLFS?

10 brokers have issued 1-year target prices for BioLife Solutions' shares. Their forecasts range from $17.00 to $55.00. On average, they anticipate BioLife Solutions' share price to reach $32.44 in the next twelve months. This suggests that the stock has a possible downside of 24.1%.
View analysts' price targets for BioLife Solutions or view Wall Street analyst' top-rated stocks.

Who are some of BioLife Solutions' key competitors?

Some companies that are related to BioLife Solutions include CONMED (CNMD), LivaNova (LIVN), Outset Medical (OM), InMode (INMD), Natus Medical (NTUS), ViewRay (VRAY), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Zynex (ZYXI), Cutera (CUTR), Stereotaxis (STXS), Edap Tms (EDAP), Soleno Therapeutics (SLNO) and BioSig Technologies (BSGM).
View all of BLFS's competitors.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:

Mr. Michael P. Rice, Pres, CEO & Director (Age 58, Pay $649.25k)
Mr. Roderick de Greef, CFO, COO & Sec. (Age 61, Pay $447.78k)
Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer (Age 49, Pay $466.97k)
Mr. Todd Berard, Chief Marketing Officer (Age 52)
Mr. Marcus Schulz, VP of Global Sales (Age 43)
Ms. Karen Foster, Chief Quality Officer (Age 61)

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Gilman Hill Asset Management LLC (0.02%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger.
View institutional ownership trends for BioLife Solutions.

Which major investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Gilman Hill Asset Management LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Greef Roderick De, James Mathers, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard, and Walter Villiger.
View insider buying and selling activity for BioLife Solutions or view top insider-selling stocks.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $42.73.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $1.40 billion and generates $27.37 million in revenue each year. The medical equipment provider earns $-1,660,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here